Welcome to our dedicated page for Becton Dickinson & news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & stock.
Becton, Dickinson and Company reports developments for a global medical technology business organized around medical essentials, connected care, biopharma systems and interventional products. Company news commonly covers fiscal results, guidance, dividends, share repurchases, debt retirement, executive appointments and strategy updates following the completed separation of the Biosciences and Diagnostic Solutions business.
BD updates also include product and customer developments across its care-delivery platforms. Recent themes include the BD® CentroVena One™ Insertion System for central venous catheter placement, BD Pyxis™ Pro medication dispensing technologies, BD Alaris™ Infusion Systems, vascular access products, medication management, patient-safety workflows and partnerships with health systems.
BD (NYSE: BDX) announced that Dr. Michael (Mike) Garrison, executive vice president and president of the Medical Essentials and BioPharma Systems segments, intends to retire after more than 20 years with the company, effective Oct. 2. Garrison has led multiple major businesses at BD, including the Medical segment, Medication Management Solutions and Surgery.
He will remain in his current role through the end of the fiscal year. BD has launched a comprehensive search for the next president of Medical Essentials, while BioPharma Systems will begin reporting directly to Chairman, CEO and President Tom Polen, reflecting its strategic role as a growth driver and streamlining BD’s operating model.
BD (NYSE:BDX) announced that management will host an audio webcast at 8 a.m. ET on Thursday, August 6, 2026, to discuss financial results for its third quarter of fiscal 2026, ended June 30, 2026, and provide an update on operations and strategy.
The live webcast and replay will be available on BD's investor relations website, where the related earnings news release and presentation materials will also be posted.
BD (NYSE:BDX) received a Vizient Innovative Technology contract for its BD CentroVena One™ Insertion System, the first all-in-one central venous catheter insertion system.
The system integrates multiple components to simplify central line placement, with 30% fewer steps and up to 50% lower maximum procedure time in simulation.
BD (NYSE:BDX) introduced the Elyra™ Thulium Fiber Laser (TFL) System, an advanced platform for kidney stone and soft tissue procedures. The system is designed to enhance efficiency, versatility, and procedural workflow for urology teams.
The air‑cooled Elyra™ and Elyra™ Plus offer efficient stone dusting, reduced stone migration, intuitive interface, quick startup, customizable presets, and an optional wireless footswitch (Plus only). Elyra™ integrates into BD’s end‑to‑end urologic stone management portfolio and is now available in the United States.
BD (NYSE: BDX) appointed Peter Menziuso as executive vice president and president of BD Interventional, effective June 1, 2026. He brings 30+ years of global healthcare leadership and previously led a $5 billion Johnson & Johnson Vision business across commercial, R&D, supply chain and other functions.
BD indicates his experience in market leadership, team building and operational excellence is expected to support continued growth and strong performance within BD Interventional.
BD (NYSE: BDX) named Vitor Roque executive vice president and chief financial officer, effective May 7, 2026. Roque served as interim CFO since December 2025 and has more than 25 years at BD. He led the global finance function and completed the separation of BD's Biosciences & Diagnostic Solutions business ahead of schedule.
Management highlights Roque's deep institutional knowledge, global experience and role advancing BD's New BD strategy and financial discipline.
BD (NYSE:BDX) reported Q2 FY2026 revenue of $4.714 billion, up 5.2% reported and 2.6% on a currency-neutral basis. Reported diluted EPS was $(0.13) while adjusted diluted EPS was $2.90. The company executed a $2.0 billion ASR, retired $2.1 billion of debt, reaffirmed revenue guidance and raised full‑year adjusted EPS guidance to $12.52–$12.72. Results are presented on a continuing operations basis following the Biosciences/Diagnostics spin‑off and Waters combination.
BD (NYSE: BDX) announced a strategic partnership with Wellstar Health System on May 5, 2026 to integrate BD Pyxis Pro dispensing and BD Alaris infusion technologies.
Powered by AI in BD Incada, the solution offers enterprise-wide medication inventory visibility, natural-language queries, customizable dashboards, and EMR interoperability with barcode-driven infusion order exchange.
BD (NYSE: BDX) announced industry recognitions for employee well-being, earning the 2026 Business Group on Health "Best Employers Award: Excellence in Health & Well-being" and additional "Excellence in Global Health & Well-being" recognition. BD also received Cigna Healthcare 2025 Gold Healthy Workforce Designation and the American Heart Association 2026 Gold Well-being Works Better recognition. These awards reflect BD's holistic global benefits, mental and financial well-being programs, and alignment with its 2030+ sustainability workforce goals.
BD (NYSE: BDX) launched the CentroVena One™ Insertion System on April 29, 2026, the first all-in-one central venous catheter insertion device. The system consolidates introducer needle, syringe, guidewire and catheter to simplify workflow, received FDA 510(k) clearance, entered the FDA Safer Technologies Program, and is now commercially available in the U.S.